Maxim Group Analysts Give Cytori Therapeutics Inc (NASDAQ:CYTX) a $5.00 Price Target
Cytori Therapeutics Inc (NASDAQ:CYTX) has been given a $5.00 target price by investment analysts at Maxim Group in a research report issued on Friday. The brokerage presently has a “buy” rating on the biotechnology company’s stock.
A number of other analysts have also issued reports on the company. ValuEngine lowered Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st. B. Riley reissued a “neutral” rating on shares of Cytori Therapeutics in a research report on Sunday, July 30th. Finally, Zacks Investment Research lowered Cytori Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th.
Shares of Cytori Therapeutics (NASDAQ CYTX) opened at 0.3497 on Friday. Cytori Therapeutics has a one year low of $0.32 and a one year high of $2.29. The company’s market capitalization is $11.36 million. The company has a 50-day moving average price of $0.82 and a 200 day moving average price of $1.22.
Cytori Therapeutics (NASDAQ:CYTX) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by $0.03. The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $2.23 million. Cytori Therapeutics had a negative net margin of 491.71% and a negative return on equity of 177.92%. The firm’s revenue for the quarter was down 18.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.43) EPS. Equities analysts anticipate that Cytori Therapeutics will post ($0.83) EPS for the current year.
An institutional investor recently raised its position in Cytori Therapeutics stock. Perkins Capital Management Inc. boosted its position in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 99.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 874,896 shares of the biotechnology company’s stock after buying an additional 435,217 shares during the period. Cytori Therapeutics comprises about 1.1% of Perkins Capital Management Inc.’s holdings, making the stock its 28th largest position. Perkins Capital Management Inc. owned 2.69% of Cytori Therapeutics worth $962,000 as of its most recent SEC filing. 10.01% of the stock is currently owned by institutional investors.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.